Non-alcoholic fatty liver disease (NAFLD) has become an epidemic, much like other non-
communicable diseases (NCDs), such as cancer, obesity, diabetes, and cardiovascular …

Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects
approximately one-quarter of the global adult population, causing a substantial burden of ill …

Nonalcoholic fatty liver disease (NAFLD), recently renamed metabolic-associated fatty liver
disease (MAFLD), is one of the most common causes of liver diseases worldwide. NAFLD is …

Gut microbiota dysbiosis has been repeatedly observed in obesity and type 2 diabetes
mellitus, two metabolic diseases strongly intertwined with non-alcoholic fatty liver disease …

Fatty liver associated with metabolic dysfunction is common, affects a quarter of the
population, and has no approved drug therapy. Although pharmacotherapies are in …

Non-alcoholic fatty liver disease (NAFLD) is considered the most common liver disease.
Dietary supplementation has become a promising strategy for managing NAFLD …

Background The incidence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing
worldwide parallel to the global obesity epidemic. NAFLD encompasses a range of liver …

Non-alcoholic fatty liver disease (NAFLD) is often the hepatic expression of metabolic
syndrome and its comorbidities that comprise, among others, obesity and insulin-resistance …

Abstract Background/Aim Non‐alcoholic fatty liver disease (NAFLD) affects approximately
25% of the global adult population. The aim of this narrative review is to describe the …

NAFLD/NASH is a sex‐dimorphic disease, with a general higher prevalence in men. Women
are at reduced risk of NAFLD compared to men in fertile age, whereas after menopause …